Marksans Pharma Limited

₹303.75As of Sun 8 Nov 2026, 12:00 UTC
NSE:MARKSANSHealthcare
Country India
PE (Fwd) •••
TSR 10Y CAGR 19.60%
Div yield 0.30%
ROE 18.60%
Drug Manufacturers (General)
Beta (5Y) 1.11
PE TTM 24.59
TSR TTM 67.28%
Mkt cap ₹137.6B
ROIC 19.99%
SE Grade™
Value
Quality
Moat
Consensus
Reference
₹315
3.76%
318.14%
Sell 0|2|11|6|8
3Q26
4Q26
1Q27
2Q27
Earnings per share₹
5.71
6.23
6.10
6.24
15.09%
20.88%
19.52%
20.13%
Revenue₹B
6.900
6.938
7.120
7.206
3.99%
4.85%
10.62%
6.08%
Peers (US$1.467B)
Cap (US$)
PE
1.879B
20.53x
830.4M
27.88x
1.479B
—
Capital
TTM
5Y
10Y
Leveragex
1.131
1.366
1.331
EBIT/Intx
0.933
0.314
0.253
Own earn%
343.11
168.61
148.04
Sh yield%
23.48
42.01
40.84
Owners
Insiders/Inst%
10.98
30.16
Short interest%
3.67
SBC / revenue%
3.11
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
9
Op margin range%
1–8
$1 testx
0.0
Incr. ROIC%
3